Navigation Links
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Date:12/9/2008

anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." During clinical studies, two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their prescribing physicians are enrolled in the Soliris Safety Registry which is part of a special risk management program that involves initial and continuing education and long-term monitoring for detection of new safety findings.

Please see full prescribing information at www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for Alexion's first product, Soliris, for all patients with PNH, and Alexion began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the EC granted marketing approval for Soliris in the European Union for all patients with PNH. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for add
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
2. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
3. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
10. NIST studies how new helium ion microscope measures up
11. SpectraCell Laboratories Now Measures Vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... German . ... have demonstrated a new kind of building block for ... chips could be based on three-dimensional arrangements of nanometer-scale ... of the semiconductor industry CMOS fabrication of silicon ... collaborators at the University of Notre Dame are exploring ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... 4 The Arcas Group, a leading ... Terwindt, MBA as Executive Vice President. He will assume ... previously served as President of Imedex, Inc."Stefan is an ... skills to our company," said Founder and President Jan ...
... Blakely & Company, LLC, a Boston-based life science investment ... III has joined the firm as senior advisor. ... firm on internal and client-related activities including private equity ... particular focus on medical device transactions. "We are ...
... Pharma Limited ("Circ Pharma") and,Elan Corporation plc ("Elan") ... Agreement to develop a chronotherapeutic formulation of Tramadol,for ... , The product incorporates ... dosing. Circ,s technology provides for,minimized delivery to the ...
Cached Biology Technology:The Arcas Group Appoints Executive Vice President 2Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company 2Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc 2
(Date:9/30/2014)... German . , ... situations such as exposure to predators. Researchers from the ... long-term study on different populations of great tits that ... temperature. High metabolic rates and low temperatures were associated ... were more likely to approach potential predators. , The ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
(Date:9/29/2014)... confirms that the exposure to tar tended to be ... cigarettes. Similarly, exposure to nicotine tended to be ... of cigarette in several countries around the world. Previous ... chemicals in the smoke of these cigarettes are lower ... of chemicals in the smoke are not necessarily linked ...
Breaking Biology News(10 mins):Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... Labs) have succeeded in combining two forms of medical ... are particularly useful for cancer research. The two techniques ... can be performed simultaneously and they give a higher ... is known as the VECTor (Versatile Emission Computed Tomography) ...
... Spanish . The University of Navarra, together ... taking part in a project to discover the origin of myelodysplasia, ... work, patients from 19 hospitals in the north of Spain ... as from England, Italy, Sweden and Germany. The aim of ...
... St. Louis, MO, June 1, 2010 Making food ... diet according to a new study comparing the nutritional content ... in the June issue of the Journal of the ... 2,000-calorie diet consisting entirely of advertised foods would contain 25 ...
Cached Biology News:TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2TV food advertisements promote imbalanced diets 2
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
... Fingerprinting II Informatix ... an optional module ... component analysis, multidimensional ... and MANOVA, and ...
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
Biology Products: